Hoth Therapeutics' HT-001 Shows Promise in Treating EGFR Inhibitor-Induced Skin Toxicities
核心洞察
Hoth Therapeutics' HT-001 demonstrated rapid improvement in papulopustular eruptions (搜索) (PPEs), a common side effect of EGFR (搜索) inhibitor therapy, in a patient with metastatic breast cancer (搜索).
The patient experienced significant symptom relief within one week of HT-001 treatment, leading to discontinuation of the therapy due to rapid healing of lesions.
Hoth has received IRB approval to proceed with a Phase IIa dose-ranging study of topical HT-001 for EGFR (搜索) inhibitor-induced skin toxicities.
Hoth Therapeutics has announced positive data from the treatment of the first patient with its lead candidate, HT-001, who was experiencing papulopustular eruptions (搜索) (PPEs), a common and debilitating side effect of EGFR (搜索) inhibitor (EGFRI) therapy in cancer patients. The 59-year-old female patient, undergoing treatment for metastatic breast cancer (搜索), witnessed significant improvement in symptoms just one week after receiving HT-001.
Rapid Symptom Relief with HT-001
Based on the rapid healing of lesions and relief of discomfort, the patient discontinued treatment after just one week. Notably, no new lesions appeared over the next three weeks, underscoring HT-001's potential as a safe and effective treatment for EGFRI-related PPEs. These results mark a significant milestone in addressing a serious unmet medical need experienced by cancer patients receiving EGFRI therapy. If successfully developed, the candidate could greatly improve the quality of life for cancer patients suffering from EGFRI-induced skin toxicities.
Addressing EGFR Inhibitor-Induced Skin Toxicities
EGFRIs, commonly used to treat various epithelial cancers, often cause skin side effects in the form of PPEs like acneiform rashes, affecting up to 90% of patients. These side effects, causing pruritus (itching) and burning, can be severe enough to disrupt or stop cancer treatments. HT-001 presents a new solution for managing these skin toxicities, providing quick symptom relief without interrupting the patient's ongoing cancer therapy.
Phase IIa Study to Evaluate HT-001
Hoth has received Institutional Review Board approval from the Montefiore Medical Center and the Dana-Farber Cancer Institute to proceed with its first-in-human mid-stage study of topical HT-001 to treat EGFRI-induced skin toxicities. The ongoing phase IIa dose-ranging study will evaluate the efficacy, safety, and tolerability of HT-001 for this indication.
Hoth's Broader Pipeline
Beyond HT-001, Hoth is developing several other next-generation therapies for different unmet medical needs. One such investigational candidate is BioLexa, which is currently being developed in a separate early-stage study for the treatment of atopic dermatitis (搜索).